Strategies to alleviate original antigenic sin responses to influenza viruses

Proceedings of the National Academy of Sciences of the United States of America

Volumn 109, Issue 34, 2012, Pages 13751-13756

  Kim, Jin Hyang ^a,b   Davis, William G ^b   Sambhara, Suryaprakash ^b   Jacob, Joshy ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

Antigen presentation; Cross reactivity; Memory T cell activation

Indexed keywords

ADJUVANT; ANTIGEN; BACTERIAL TOXIN; CPG OLIGODEOXYNUCLEOTIDE; NEUTRALIZING ANTIBODY; SIALIDASE; SQUALENE;

ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ANTIBODY TITER; ANTIGEN PRESENTATION; ARTICLE; BORDETELLA PERTUSSIS; CONTROLLED STUDY; DENDRITIC CELL; IMMUNE RESPONSE; IMMUNIZATION; INFLUENZA A (H1N1); INFLUENZA VIRUS; LETHALITY; MOUSE; NANOEMULSION; NONHUMAN; ORIGINAL ANTIGENIC SIN; PRIORITY JOURNAL; VIRUS STRAIN;

ANIMALS; ANTIBODY FORMATION; ANTIGEN PRESENTATION; BORDETELLA; CELL LINE; CPG ISLANDS; DOGS; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; HUMANS; IMMUNE SYSTEM; IMMUNIZATION; IMMUNOLOGIC MEMORY; INFLUENZA A VIRUS, H1N1 SUBTYPE; MICE; MICE, INBRED BALB C; OLIGONUCLEOTIDES; ORTHOMYXOVIRIDAE; PERTUSSIS TOXIN;

EID: 84865289172     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.0912458109     Document Type: Article

References (36)

1. Davenport FM, Hennessy AV, Francis T, Jr. (1953) Epidemiologic and immunologic significance of age distribution of antibody to antigenic variants of influenza virus. J Exp Med 98:641-656.
2. Virelizier JL, Allison AC, Schild GC (1974) Antibody responses to antigenic determinants of influenza virus hemagglutinin. II. Original antigenic sin: A bone marrowderived lymphocyte memory phenomenon modulated by thymus-derived lymphocytes. J Exp Med 140:1571-1578.
3. Virelizier JL, Postlethwaite R, Schild GC, Allison AC (1974) Antibody responses to antigenic determinants of influenza virus hemagglutinin. I. Thymus dependence of antibody formation and thymus independence of immunological memory. J Exp Med 140:1559-1570.
4. Webster RG (1966) Original antigenic sin in ferrets: The response to sequential infections with influenza viruses. J Immunol 97:177-183.
5. Fazekas de St Groth S, Webster RG (1966) Disquisitions on Original Antigenic Sin. II. Proof in lower creatures. J Exp Med 124:347-361.
6. Herzenberg LA, Tokuhisa T, Herzenberg LA (1980) Carrier-priming leads to hapten-specific suppression. Nature 285:664-667.
7. Di John D, et al. (1989) Effect of priming with carrier on response to conjugate vaccine. Lancet 2:1415-1418.
8. Renjifo X, et al. (1998) Carrier-induced, hapten-specific suppression: A problem of antigen presentation? J Immunol 161:702-706.
9. Roake JA, et al. (1995) Dendritic cell loss from nonlymphoid tissues after systemic administration of lipopolysaccharide, tumor necrosis factor, and interleukin 1. J Exp Med 181:2237-2247.
10. De Smedt T, et al. (1996) Regulation of dendritic cell numbers and maturation by lipopolysaccharide in vivo. J Exp Med 184:1413-1424.
11. Finger H, Emmerling P, Schmidt H (1967) Accelerated and prolongated multiplication of antibody-forming spleen cells by Bordetella pertussis in mice immunized with sheep red blood cells. Experientia 23:591-592.
12. Herzenberg LA, Tokuhisa T (1982) Epitope-specific regulation. I. Carrier-specific induction of suppression for IgG anti-hapten antibody responses. J Exp Med 155:1730-1740.
13. Vogel FR, et al. (1987) Modulation of carrier-induced epitopic suppression by Bordetella pertussis components and muramyl peptide. Cell Immunol 107:40-51.
14. Hou W, et al. (2003) Pertussis toxin enhances Th1 responses by stimulation of dendritic cells. J Immunol 170:1728-1736.
15. Lipford GB, et al. (1997) CpG-containing synthetic oligonucleotides promote B and cytotoxic T cell responses to protein antigen: A new class of vaccine adjuvants. Eur J Immunol 27:2340-2344.
16. Roman M, et al. (1997) Immunostimulatory DNA sequences function as T helper-1- promoting adjuvants. Nat Med 3:849-854.
17. Hartmann G, Weiner GJ, Krieg AM (1999) CpG DNA: A potent signal for growth, activation, and maturation of human dendritic cells. Proc Natl Acad Sci USA 96:9305-9310.
18. Chu RS, Targoni OS, Krieg AM, Lehmann PV, Harding CV (1997) CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity. J Exp Med 186:1623-1631.
19. Sparwasser T, et al. (1998) Bacterial DNA and immunostimulatory CpG oligonucleotides trigger maturation and activation ofmurine dendritic cells.Eur J Immunol 28:2045-2054.
20. Mosca F, et al. (2008) Molecular and cellular signatures of human vaccine adjuvants. Proc Natl Acad Sci USA 105:10501-10506.
21. Tritto E, Mosca F, De Gregorio E (2009) Mechanism of action of licensed vaccine adjuvants. Vaccine 27:3331-3334.
22. Podda A (2001) The adjuvanted influenza vaccines with novel adjuvants: Experience with the MF59-adjuvanted vaccine. Vaccine 19:2673-2680.
23. Galli G, et al. (2009) Fast rise of broadly cross-reactive antibodies after boosting long-lived human memory B cells primed by an MF59 adjuvanted prepandemic vaccine. Proc Natl Acad Sci USA 106:7962-7967.
24. Vesikari T, et al. (2011) Oil-in-water emulsion adjuvant with influenza vaccine in young children. N Engl J Med 365:1406-1416.
25. Clark TW, et al. (2009) Trial of 2009 influenza A (H1N1) monovalent MF59-adjuvanted vaccine. N Engl J Med 361:2424-2435.
26. Kim JH, Skountzou I, Compans R, Jacob J (2009) Original antigenic sin responses to influenza viruses. J Immunol 183:3294-3301.
27. Jensen KE, Davenport FM, Hennessy AV, Francis T, Jr. (1956) Characterization of influenza antibodies by serum absorption. J Exp Med 104:199-209.
28. Davenport FM, Hennessy AV (1956) A serologic recapitulation of past experiences with influenza A; antibody response to monovalent vaccine. J Exp Med 104:85-97.
29. Fazekas de St Groth S, Webster RG (1966) Disquisitions of Original Antigenic Sin. I. Evidence in man. J Exp Med 124:331-345.
30. Baldo V, Baldovin T, Floreani A, Carraro AM, Trivello R; Family Medicine Group of Pianiga (2007) MF59-adjuvanted influenza vaccine confers superior immunogenicity in adult subjects (18-60 years of age) with chronic diseases who are at risk of postinfluenza complications. Vaccine 25:3955-3961.
31. Doucett VP, et al. (2005) Enumeration and characterization of virus-specific B cells by multicolor flow cytometry. J Immunol Methods 303:40-52.
32. Van Uden JH, Tran CH, Carson DA, Raz E (2001) Type I interferon is required to mount an adaptive response to immunostimulatory DNA. Eur J Immunol 31:3281-3290.
33. Gerhard W (2001) The role of the antibody response in influenza virus infection. Curr Top Microbiol Immunol 260:171-190.
34. Topham DJ, Tripp RA, Doherty PC (1997) CD8+ T cells clear influenza virus by perforin or Fas-dependent processes. J Immunol 159:5197-5200.
35. Doherty PC, Turner SJ, Webby RG, Thomas PG (2006) Influenza and the challenge for immunology. Nat Immunol 7:449-455.
36. Garg S, Oran AE, Hon H, Jacob J (2004) The hybrid cytomegalovirus enhancer/chicken beta-actin promoter along with woodchuck hepatitis virus posttranscriptional regulatory element enhances the protective efficacy of DNA vaccines. J Immunol 173:550-558.